In last week’s Pharmacogenomics Reporter, the story “Roche Looks to Take Lead in Emerging 'Theranostics' Space With p53 AmpliChip,” erroneously reported that Roche is already using the p53 chip to stratify patients during clinical trials of Nutlin. In fact, the company is using the test to stratify patients in trials of other drugs in the company’s pipeline. The company still plans on forming partnerships with other pharma companies interested in the p53 chip.
Correction: May 5, 2005
May 05, 2005